MEI also has the worldwide rights to distribute and market the drug for all oral and injectable anti-cancer treatments. Novogen would retain up to an 88 percent shareholding in MEI for at least six months. The CEO of MEI and managing director of Novogen, Mr Christopher Naughton, said the anti-cancer focus of MEI would facilitate the commercialisation of phenoxodiol and make strategic or equity partnerships with major pharmaceutical collaborators easier to execute.
Prostate cancer is the main cancer target for phenoxodiol.
Novogen is a Sydney, Australia-based pharmaceutical company with offices in Stamford, Connecticut. Novogen is a leader in the field of phenolic drug research and development. No part of this publication may be redistributed in any form without prior permission. Terms and conditions for users . Privacy policy .